webinar register page

Webinar banner
IPVS Webinar - HPV latency: more questions than answers
The ability of papillomaviruses to establish infection at human epithelial sites that is largely undetectable by most routine molecular diagnostic tests is indisputable. However, there remains considerable disagreement about what this ‘test negative, infection positive’ state represents (i.e., latency or very low viral copy persistence), how common it is at the anogenital or oral/oropharyngeal sites in women and men, and what risk of HPV-associated cancers this state of infection confers to an individual across the lifespan.

Drs. Bettie Steinberg and Patti Gravitt will take an interdisciplinary look at the evidence and lead a discussion to help the papillomavirus community reflect on what is known and unknown about HPV latency, why it may be important to accelerate research efforts to address the remaining uncertainties, and how we may frame the research questions using novel study designs and interdisciplinary perspectives.
* Required information
Loading

Speakers

Bettie M. Steinberg, Professor
The Feinstein Institutes for Medical Research
Dr. Steinberg’s research focuses on the role of HPVs in benign and malignant tumors of the head and neck. Her research has been recognized by multiple awards, including the Elliot Osserman Award from the Israel Cancer Research Fund, the Karl Storz Award from the American Society of Pediatric Otolaryngology, the Israel Cancer Research Fund Award for Women of Excellence, and the Lifetime Achievement Award from the International Papillomavirus Society. She is Professor at The Feinstein Institute for Medical Research and the Elmezzi Graduate School of Molecular Medicine, and Professor of Molecular Medicine and Otolaryngology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell.
Patti Gravitt, Ph.D., M.S
Deputy Director, US National Cancer Institute Center for Global Health
Patti E. Gravitt, Ph.D., M.S., joined NCI as Deputy Director of the Center for Global Health in July 2021. In this role she leads implementation science efforts and provides scientific and programmatic direction across our research, training, partnership, and dissemination goals. Dr. Gravitt is a molecular epidemiologist whose research in human papillomavirus and cervical cancer spans the translational spectrum from the natural history of genital infection across the lifespan to the translation of evidence-based prevention tools to low- and middle-income countries. Her efforts have contributed significantly to the evidence base regarding the efficacy of alternative cervical cancer screening strategies, being among the first to show an increase in screening coverage afforded by self-collected sampling and HPV testing and the relatively poor performance of visual inspection methods where intensive international technical assistance and training are not available.
Margaret Stanley, Professor
University of Cambridge
Margaret Stanley is Emeritus Professor of Epithelial Biology, Director of Research in the Department of Pathology, University of Cambridge, Honorary Fellow of Christs College, Fellow of the Academy of Medical Sciences and Honorary Fellow of the UK Royal College of Obstetricians and Gynaecologists. She has a lifetime award from the American Society for Colposcopy and Cytopathology (ASCCP) and International Papillomavirus Society (IPVS), was a member of the UK Biology and Biotechnology Science Research Council, a member of the Spongiform Encephalopathies Advisory Committee that advised the UK government on prion diseases. In 2004 she was awarded the OBE for services to Virology. She has been and is a member of the Expert Groups advising on HPV vaccines for WHO SAGE, acted as the invited HPV expert for the HPV subcommittee of the UK JCVI, invited expert for ECDC and is on the HPV vaccines advisors group for the Gates Foundation. She has published extensively and is at present on the E